Cancer patients are especially vulnerable to COVID and would benefit from the protection the vaccine offers, says Gary Schwartz, MD, deputy director of the Herbert Irving Comprehensive Cancer Center.
A new study has found that up to 20% of aggressive brain cancers are fueled by overactive mitochondria and new drugs in development may be able to starve the cancers.
A new study conducted at Columbia and other centers found that 80% of patients with a type of slow-growing lymphoma achieved a complete remission with a single infusion of CAR T-cell immunotherapy.
In a phase 1 study, eight out of 12 patients with relapsed and/or refractory blood cancers responded to a combination of two common chemotherapy drugs.
Dr. Drake studies the body’s immunological response to radiation therapy and how immunotherapy and radiation therapy can be used in concert to treat cancer.
Adding a new drug called olaratumab to traditional chemotherapy increased survival in sarcoma patients, researchers at Columbia University Medical Center have found.
The three-dimensional structure could help researchers develop novel therapies and diagnostic tools for diseases that are caused by a malfunction in calcium adsorption.
According to a new report published in JAMA Oncology, women with BRCA1 mutations have a higher risk of developing an aggressive type of uterine cancer.
$4 million grant gives Columbia, Weill Cornell Medicine, NewYork-Presbyterian, and NYC Health + Hospitals key role in precision medicine cohort program.